← Back to Search

Serotonin and Norepinephrine Reuptake Inhibitor

Venlafaxine for Meniere's Disease

Phase 2 & 3
Waitlist Available
Led By Habib Rizk, MD
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will test if venlafaxine is an effective treatment for Meniere's disease. The study is double-blind, meaning neither the participants nor the researchers will know who is receiving the real drug or the placebo.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Score on Cognitive Failure Questionnaire (CFQ)
Change in Score on Dizziness Handicap Inventory (DHI)
Change in Score on Neuropsychological Vertigo Inventory (NVI)
+6 more

Side effects data

From 2009 Phase 4 trial • 220 Patients • NCT00177671
1%
Suicide Attempt
1%
Myocardial infarcation with congestive heart failure
1%
stroke
100%
80%
60%
40%
20%
0%
Study treatment Arm
Donepezil
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Venlafaxine ArmExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venlafaxine
2007
Completed Phase 4
~3259640

Find a Location

Who is running the clinical trial?

American Hearing Research FoundationUNKNOWN
Cures within Reach FoundationUNKNOWN
Medical University of South CarolinaLead Sponsor
940 Previous Clinical Trials
7,396,954 Total Patients Enrolled

Media Library

Meniere's Disease Research Study Groups: Venlafaxine Arm, Placebo
Meniere's Disease Clinical Trial 2023: Venlafaxine Highlights & Side Effects. Trial Name: NCT04218123 — Phase 2 & 3
Venlafaxine (Serotonin and Norepinephrine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04218123 — Phase 2 & 3
~8 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top